Cargando…
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC
With five histone deacetylase (HDAC) inhibitors approved for cancer treatment, proteolysis-targeting chimeras (PROTACs) for degradation of HDAC are emerging as an alternative strategy for HDAC-targeted therapeutic intervention. Herein, three bestatin-based hydroxamic acids (P1, P2 and P3) were desig...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662900/ https://www.ncbi.nlm.nih.gov/pubmed/33126591 http://dx.doi.org/10.3390/molecules25214991 |